Vimian Group AB (VIMIAN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vimian Group AB (VIMIAN) has a cash flow conversion efficiency ratio of 0.080x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr56.57 Million ≈ $6.09 Million USD) by net assets (Skr708.80 Million ≈ $76.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VIMIAN market cap overview for the company's overall valuation and market capitalisation.
Vimian Group AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Vimian Group AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vimian Group AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vimian Group AB ranked by their cash flow conversion efficiency. Explore Vimian Group AB earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Uniti Group Inc.
LSE:0LJB
|
0.711x |
|
Bet Shemesh Engines Holdings 1997 Ltd
TA:BSEN
|
-0.021x |
|
Ruentex Industries Ltd
TW:2915
|
0.003x |
|
Tung Ho Steel Enterprise Corp
TW:2006
|
0.038x |
|
Spartan Resources Ltd
AU:SPR
|
-0.015x |
|
Zhejiang Weixing Industrial Development Co Ltd
SHE:002003
|
0.063x |
|
Intralot S.A. Integrated Lottery Systems and Services
AT:INLOT
|
0.306x |
|
Bomin Electronics Co Ltd
SHG:603936
|
0.009x |
Annual Cash Flow Conversion Efficiency for Vimian Group AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vimian Group AB from 2018 to 2025. View Vimian Group AB share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr708.80 Million ≈ $76.28 Million |
Skr105.70 Million ≈ $11.38 Million |
0.149x | +81.34% |
| 2024-12-31 | Skr706.50 Million ≈ $76.03 Million |
Skr58.10 Million ≈ $6.25 Million |
0.082x | +251.58% |
| 2023-12-31 | Skr526.71 Million ≈ $56.68 Million |
Skr-28.58 Million ≈ $-3.08 Million |
-0.054x | -203.20% |
| 2022-12-31 | Skr481.50 Million ≈ $51.82 Million |
Skr25.31 Million ≈ $2.72 Million |
0.053x | +17.74% |
| 2021-12-31 | Skr358.64 Million ≈ $38.60 Million |
Skr16.01 Million ≈ $1.72 Million |
0.045x | +155.06% |
| 2020-12-31 | Skr274.25 Million ≈ $29.51 Million |
Skr4.80 Million ≈ $516.66K |
0.018x | -41.17% |
| 2019-12-31 | Skr52.02 Million ≈ $5.60 Million |
Skr1.55 Million ≈ $166.59K |
0.030x | +128.80% |
| 2018-12-31 | Skr19.59 Million ≈ $2.11 Million |
Skr-2.02 Million ≈ $-217.81K |
-0.103x | -- |
About Vimian Group AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic… Read more